Abcam, ab263272, Human NARF (IOP2) knockout HeLa cell lysate

Size: 1Kit
NARF KO cell lysate available now. KO validated by. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 16 bp deletion in exon3 and 1 bp deletion in exon3 and 5 bp deletion in exon3.
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, 16 bp deletion in exon3 and 1 bp deletion in exon3 and 5 bp deletion in exon3.,
Disease:Adenocarcinoma

Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-NARF, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
IOP2 also known by alternate names programmable cell death protein 6-interacting protein or PDCD6IP plays a role in cellular mechanisms involving vesicle trafficking and endocytosis. This protein approximately weighs 80 kDa and is widely expressed in various tissues including brain liver and heart. IOP2 exhibits interactions with other proteins within the cell enabling the formation of multitumor suppressor complexes that regulate cell survival and division.
Biological function summary
IOP2 functions in intracellular signaling and membrane dynamics. It participates as a component of the ESCRT (endosomal sorting complexes required for transport) machinery. In this context IOP2 facilitates the sorting of ubiquitinated transmembrane proteins into the internal vesicles of multivesicular bodies. Its activity in this complex highlights the regulation of down-regulating surface receptors and contributing to the cellular homeostasis.
Pathways
IOP2 interacts with mechanisms controlling cellular growth and apoptosis. One of the significant pathways includes the mitogen-activated protein kinase (MAPK) signaling which influences cell proliferation. Within this pathway IOP2 relates to proteins such as ERK1/2 playing a role in the signal transduction processes. Additionally the protein contributes to the regulation of PI3K/AKT pathway impacting cell survival through its interactions within the signaling network.
IOP2 exhibits connection to cancer and neurodegenerative disorders. In oncological contexts altered IOP2 expression links with esophageal squamous cell carcinoma suggesting a role in tumor progression. Additionally in neurodegenerative conditions IOP2 interaction with Alzheimer’s disease-related proteins like amyloid precursor protein (APP) reflects its involvement in pathological processes. Changes in IOP2 function or expression may therefore serve as potential biomarkers or targets for therapeutic intervention in these diseases.